Sugi Predict

Sugi Predict / Compounds / SCHEMBL17815795

SCHEMBL17815795

SCHEMBL17815795

CN(c1ccc(C(N)=O)cc1)c1ncnc(Cl)c1N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 3/20 0.36
▸ MAP2K7 O14733 1/20 0.36
▸ EGFR P00533 5/20 0.35
▸ PDGFRB P09619 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ CSF1R P07333 3/20 0.35
▸ NNMT P40261 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MKNK1 Q9BUB5 2/20 0.35
▸ MKNK2 Q9HBH9 2/20 0.35
▸ CHEK2 O96017 1/20 0.34
▸ PARP10 Q53GL7 1/20 0.33
▸ ROCK1 Q13464 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ WDR5 P61964 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ RXRA P19793 1/20 0.33
▸ NR4A2 P43354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5243561 0.81 EGFR (0.46) EGFRPDGFRBKDRCSF1R
SCHEMBL17815790 0.81 PRMT1 (0.43) MAP4K4MAP2K7SMN1; SMN2KMT2A
SCHEMBL8856262 0.69 HTT (0.42) CHEK2KMT2A
SCHEMBL17802606 0.69 MKNK1 (0.54) MAP4K4EGFRKDRMKNK1ROCK1
SCHEMBL17815583 0.69 LMNA (0.41) MAP4K4NNMTSMN1; SMN2MKNK1MKNK2
SCHEMBL17802571 0.69 PARP10 (0.51) MAP4K4SMN1; SMN2PARP10KMT2A
SCHEMBL17815794 0.69 MAPT (0.43) CSF1RKMT2ARXRANR4A2
SCHEMBL19533483 0.68 HPGD (0.42) EGFRCSF1RCHEK2
SCHEMBL19533484 0.67 HPGD (0.47) EGFRCSF1RCHEK2
SCHEMBL17815800 0.66 AURKA (0.56) HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10414768-B2 Compounds for treating cystic fibrosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2019-09-17 — — US disclosed
US-10414768-B2 Compounds for treating cystic fibrosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2019-09-17 — — US disclosed
US-20170362239-A1 COMPOUNDS FOR TREATING CYSTIC FIBROSIS UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-12-21 — — US disclosed
US-20170362239-A1 COMPOUNDS FOR TREATING CYSTIC FIBROSIS UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-12-21 — — US disclosed
US-20170362239-A1 COMPOUNDS FOR TREATING CYSTIC FIBROSIS UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-12-21 — — US disclosed
WO-2016087665-A2 COMPOUNDS FOR TREATING CYSTIC FIBROSIS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2016-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414768-B2 Compounds for treating cystic fibrosis CFTR, ABCB11, SLC26A4 MAP4K4 3526/4885MAP2K7 3637/4885EGFR 1817/4885
US-20170362239-A1 COMPOUNDS FOR TREATING CYSTIC FIBROSIS CFTR, ABCB11, SLC26A4 MAP4K4 3526/4885MAP2K7 3637/4885EGFR 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.